



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Lucicebtide

Cat. No.:	HY-P10376	
CAS No.:	2407100-74-5	
Molecular Formula:	C <sub>208</sub> H <sub>345</sub> N <sub>69</sub> O <sub>55</sub> S	d-{Val-Ala-Glu-Ala-Arg-Glu-Glu-Leu-Glu-Arg-Leu-Glu-Ala-Arg-Leu-Gly-Gln-Ala-Arg-Gly-Arg-Leu-Glu-Ala-Arg-Leu-Gly-Gln-Ala-Arg-Gly-Gly-Glu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Leu-Lys-Leu-Gln-Arg}
Molecular Weight:	4724.46	
Sequence:	d-{Val-Ala-Glu-Ala-Arg-Glu-Glu-Leu-Glu-Arg-Leu-Glu-Ala-Arg-Leu-Gly-Gln-Ala-Arg-Gly-Glu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Leu-Lys-Leu-Gln-Arg}	
Sequence Shortening:	d-{Val-Ala-Glu-Ala-Arg-Glu-Glu-Leu-Glu-Arg-Leu-Glu-Ala-Arg-Leu-Gly-Gln-Ala-Arg-Gly-Glu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Leu-Lys-Leu-Gln-Arg}	
Target:	Others	
Pathway:	Others	
Storage:	Sealed storage, away from moisture	
	Powder -80°C 2 years	
	-20°C 1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

### SOLVENT & SOLUBILITY

**In Vitro** DMSO : 0.99 mg/mL (0.21 mM; ultrasonic and adjust pH to 5 with 1 M HCL)

### BIOLOGICAL ACTIVITY

**Description** Lucicebtide (Compound ST101) is a selective antagonist for CCAAT/enhancer binding protein  $\beta$  (C/EBP $\beta$ ). Lucicebtide binds to the leucine zipper domain of C/EBP $\beta$ , prevents its dimerization, and ubiquitin-dependently degrades C/EBP $\beta$ . Lucicebtide arrests cell cycle at G0/G1 phase. Lucicebtide exhibits cytotoxicity in cancer cells. Lucicebtide exhibits good pharmacokinetic characters and inhibits tumor growth in mouse model<sup>[1]</sup>.

### REFERENCES

[1]. Danishi E, et al., Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein  $\beta$ . Mol Cancer Ther. 2022 Nov 3;21(11):1632-1644.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA